Advertisement


Patricia J. Goldsmith on Patient Access and Engagement: Results of the CancerCare Report

2016 ASCO Annual Meeting

Advertisement

Patricia J. Goldsmith, Chief Executive Officer of CancerCare, which provides free, professional support services to anyone affected by cancer, discusses findings from six distinct surveys with input from more than 3,000 individuals at varying stages of their cancer experience.



Related Videos

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Gynecologic Cancers

Jonathan A. Ledermann, MD, and Ursula A. Matulonis, MD, on Olaparib Maintenance Monotherapy for Ovarian Cancer

Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).

Global Cancer Care

Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).

Global Cancer Care

Eduardo L. Cazap, MD, PhD, and Mary Gospodarowicz, MD, on The South American Perspective of Cancer Research

Eduardo L. Cazap, MD, PhD, of the Latinamerican & Caribbean Society of Medical Oncology, and Mary Gospodarowicz, MD, of the Princess Margaret Hospital, discuss oncology from an international point of view.

CNS Cancers

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).

Advertisement

Advertisement




Advertisement